Celgene 2018 revenue forecast shy of analysts' estimates


Celgene Corp on Monday forecast 2018 total revenue that fell short of analysts' estimates, sending the company's shares down 3 percent. The company, which is buying Impact Biomedicines for as much as $7 billion, said it expects full-year revenue of $14.4 billion to $14.8 billion, compared with analysts' average estimate of $14.83 billion, according to Thomson Reuters I/B/E/S.



from Biotech News